Parkinson’s disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function

Vanessa A. Morais1,2, Patrik Verstreken1,2*, Anne Roethig3, Joël Smet4, An Snellinx1,2, Mieke Vanbrabant1,2, Dominik Haddad1,2, Christian Frezza5, Wim Mandemakers1,2, Daniela Vogt-Weisenhorn3, Rudy Van Coster4, Wolfgang Wurst3, Luca Scorrano6, Bart De Strooper1,2*

Keywords: Complex I; mitochondrial dysfunction; Parkinson’s disease; reserve pool deficit

DOI 10.1002/emmm.200900006

Mutations of the mitochondrial PTEN (phosphatase and tensin homologue)-induced kinase1 (PINK1) are important causes of recessive Parkinson disease (PD). Studies on loss of function and overexpression implicate PINK1 in apoptosis, abnormal mitochondrial morphology, impaired dopamine release and motor deficits. However, the fundamental mechanism underlying these various phenotypes remains to be clarified. Using fruit fly and mouse models we show that PINK1 deficiency or clinical mutations impact on the function of Complex I of the mitochondrial respiratory chain, resulting in mitochondrial depolarization and increased sensitivity to apoptotic stress in mammalian cells and tissues. In Drosophila neurons, PINK1 deficiency affects synaptic function, as the reserve pool of synaptic vesicles is not mobilized during rapid stimulation. The fundamental importance of PINK1 for energy maintenance under increased demand is further corroborated as this deficit can be rescued by adding ATP to the synapse. The clinical relevance of our observations is demonstrated by the fact that human wild type PINK1, but not PINK1 containing clinical mutations, can rescue Complex I deficiency. Our work suggests that Complex I deficiency underlies, at least partially, the pathogenesis of this hereditary form of PD. As Complex I dysfunction is also implicated in sporadic PD, a convergence of genetic and environmental causes of PD on a similar mitochondrial molecular mechanism appears to emerge.

INTRODUCTION

PD is a common progressive neurodegenerative movement disorder characterized by postural instability, rigidity, tremor and bradykinesia (Dawson & Dawson, 2003; Thomas & Beal, 2007). The pathological hallmark of PD is loss of dopaminergic neurons in the substantia nigra and the presence of eosinophilic cytoplasmic inclusions of misfolded proteins termed Lewy bodies in affected brain areas. The etiology of PD remains unknown, although clinical and experimental evidence implicates the involvement of abnormal protein aggregation, oxidative stress and mitochondrial dysfunction (Beal, 2003; Jenner & Olanow, 1996; Kosel et al, 1999; Zhang et al, 2000).

Over the years, the case for mitochondrial impairment in at least part of the pathogenesis of PD has become quite persuasive.
(reviewed in Mandemakers et al, 2007). For instance, several mitochondrial toxins that block Complex I cause Parkinsonism in humans and laboratory animals and are widely used to create PD animal models (Panov et al, 2005). Complex I (NADH:ubiquinone oxidoreductase, EC 1.6.5.3; NADH, nicotinamide adenine dinucleotide) is the first and the largest (~980 kDa) complex of the electron transport chain (ETC). In mammals, it consists of 46 subunits, seven of which are encoded by mitochondrial DNA (Vogel et al, 2007). Complex I transfers electrons from NADH to ubiquinone while pumping protons across the inner mitochondrial membrane contributing to the electrochemical proton gradient used by F, F ATP synthase (Complex V) to produce ATP from ADP and inorganic phosphate. In addition, Complex I may also leak reactive oxygen species (ROS), resulting in cellular damage (Smeitink et al, 2004). Interestingly, Complex I deficiency and oxidative damage are frequently observed in affected neurons of PD patients (Parker & Swerdlow, 1998).

The involvement of mitochondria in PD is also deduced from studies demonstrating how other nuclear genes associated with the familial forms of PD can directly or indirectly affect mitochondrial function. α-Synuclein, the major component of Lewy bodies, appears to contain an amino-terminal mitochondrial targeting sequence (Devi et al, 2008) and acidification of the cytosol or overexpression of α-synuclein itself can cause localization of the protein to mitochondria (Cole et al, 2008; Shavali et al, 2008). Additionally, α-synuclein-null mice demonstrate increased resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydrodipyridine (MPTP) (Dauer & Przedborski, 2003), whereas transgenic α-synuclein animal models treated with MPTP present swollen, morphologically abnormal mitochondria (Song et al, 2004). Parkin, an E3 ubiquitin ligase, is another gene implicated in autosomal recessive PD (Shimura et al, 2000). Parkin-null mice and Parkin Drosophila mutants develop apoptotic muscle degeneration with mitochondrial pathology and decreased resistance to oxidative stress (Greene et al, 2003; Palacino et al, 2004; Pesah et al, 2004). Furthermore, in a recent study it was shown that Parkin is involved in autophagy of dysfunctional mitochondria (Narendra et al, 2008), which might provide a mechanistic explanation for the genetic interaction between Parkin and Pink1 in Drosophila (Clark et al, 2006; Poole et al, 2008; Yang et al, 2006). Another PD-related gene, DJ-1 appears to function as an oxidative stress sensor as it is translocated under those conditions from the nucleus to the mitochondrial matrix and intramembrane space (Zhang et al, 2005). Finally, mutations in the leucine-rich repeat serine/threonine protein kinase 2 (LRRK2) are the most common known cause of familial and, interestingly, also sporadic PD (Gandhi et al, 2008). Subcellular fractionation indicates that approximately 10% of the total LRRK2 protein is localized to the mitochondrial outer membrane (Biskup et al, 2006; West et al, 2005), and LRRK2-mediated cell toxicity might involve cytochrome c release and caspase 3 activation (Iaccarino et al, 2007).

Although available data on α-synuclein, LRRK2 and Parkin already make a strong case for a role of mitochondria in PD, the most convincing evidence for the involvement of mitochondrial dysfunction is the presence of mutations in the mitochondrial serine/threonine kinase PINK1 that cause recessive hereditary PD in several families (Beilina et al, 2005; Silvestri et al, 2005). PINK1 is involved in the phosphorylation of the mitochondrial proteins TRAP1 (TNF receptor-associated protein 1), Htr2a (5-hydroxytryptamine (serotonin) receptor 2a)/OMI (Plun-Favreau et al, 2007; Pridgeon et al, 2007) and also Parkin (Kim et al, 2008), and associates with Hsp90 (heat shock protein 90)/Cdc37 (cell division cycle 37) chaperones (Moriwaki et al, 2008; Weihofen et al, 2007). Pink1 deficient mice reveal impaired dopamine release (Kitada et al, 2007), deficient mitochondrial respiration and increased sensitivity to oxidative stress (Gautier et al, 2008), while overexpression and loss of function studies suggest an anti-apoptotic activity for PINK1 (Deng et al, 2005; Lin & Kang, 2008; Petit et al, 2005). Additionally, studies in Drosophila and in HeLa cells indicate that Pink1 deficiency leads to altered mitochondrial morphology (Clark et al, 2006; Exner et al, 2007; Park et al, 2006; Poole et al, 2008; Yang et al, 2006). Evidence that pink1 genetically interacts with the fission/fusion machinery of mitochondria has supported the hypothesis that Pink1 deficiency affects various mitochondrial functions via interference with mitochondrial dynamics (Deng et al, 2008; Yang et al, 2008). It should be noted however that genetic interactions between pink1 and drp1 (dynamin related protein) or fis1 (fission 1), genes implicated in mitochondrial fission (Yoon et al, 2003), do not imply necessarily that pink1 is in the same molecular pathway as these proteins. Indeed studies performed on fibroblasts from patients carrying the homozygous W437X (Trp 437→Xxx) nonsense PINK1 mutation revealed a normal mitochondrial tubular network (Piccoli et al, 2008).

The interpretation of the various phenotypes caused by Pink1 deficiency or mutation thus remains somewhat controversial and the question of the fundamental mechanism underlying the various reported phenotypes needs to be further tested. We set out in the current work to investigate systematically the impact of Pink1 deficiency on fundamental mitochondrial functions and demonstrate that the earliest and most consistent defect lies in Complex I. We discuss how this deficit can explain the various phenotypes described previously in Pink1 deficient flies and mice.

RESULTS

Drosophila pink1 mutants fail to maintain normal synaptic transmission and show defects in reserve pool function

We used previously characterized pink1 mutant flies (Park et al, 2006), which display motor disturbances and structural changes of mitochondria. Loss of mitochondria at synapses has been implicated in specific defects in neurotransmission at Drosophila neuromuscular junction (NMJ) (Verstreken et al, 2005). We therefore measured neurotransmission using current clamp recordings at third instar larval NMJs in 2 or 0.5 mM Ca2+. As shown in Fig 1A–D, pink1 null mutants did not show deficits in neurotransmitter release or in amplitude or frequency of the spontaneous vesicle fusion measured in 0.5 mM Ca2+ and tetrodotoxin (TTX) (Fig 1E–H) implying that basal release characteristics, such as synaptic vesicle size, neurotransmitter...
filling and post-synaptic receptor clustering, are not significantly affected in the mutants. However, when pink1 mutants were stimulated at a higher and more intense frequency of 10 Hz, a small but significant progressive decline in synaptic transmission (Fig 11) was observed. This might be caused by reduced endocytosis and inefficient replenishment of the cycling vesicle pool (ECP) or, alternatively, by defects in the utilization of the reserve pool (RP) that becomes mobilized only during high frequency stimulation (Kuromi & Kidokoro, 2002). FM1–43 dye reversibly binds membranes and is internalized in synaptic vesicles. Using specific stimulation paradigms (Kuromi & Kidokoro, 2002) this dye differentially labels both the vesicle pools. The vesicle endocytosis and labelling of the ECP in pink1B9 is not affected (Fig 2A and B); however, the RP cannot be efficiently labelled in pink1B9 mutants (Fig 2C, D). This was rescued by expressing human PINK1 in the affected neurons (Fig 2C and D). These specific defects at pink1 deficient synapses are very reminiscent, albeit less severe, to those observed in Drosophila drp1 mutants where most of the mitochondria fail to localize to synapses (Verstreken et al, 2005).

The pink1B9 flies harbour lower overall ATP levels (Clark et al, 2006). Thus, we forward filled control and pink1B9 motor neurons with ATP. As shown in Fig 2E and F, pink1B9 mutants and controls internalized similar amounts of FM1–43 dye in the presence of ATP. Subsequent unloading of ECP vesicles showed an increase in FM1–43 retention in the ATP-treated pink1B9 mutants compared to the non-ATP treated mutants (compare pink1B9 ‘unload’ in Fig 2C with Fig 2E; as well as pink1B9 black bars in Fig 2D with Fig 2F). Thus, impaired RP mobilization in pink1B9 mutants is, at least in part, caused by synaptic ATP depletion, similar to the defects observed in the mitochondria depleted drp1 mutant synapses (Verstreken et al, 2005).

Absence of PINK1 does not lead to dramatic changes in mitochondrial fragmentation

Absence of Pink1 and also deficiencies in Drp1, have been associated with alterations in mitochondrial morphology. To visualize mitochondria we used a mitochondrial targeted EGFP (Verstreken et al, 2005), but no alterations at pink1B9 mutant NMJs were observed, nor did we observe a difference in synaptic mitochondrial localization (Fig 3A and B) (Li et al, 2004; Verstreken et al, 2005). Also in fibroblasts obtained from Pink1 mouse mutants expressing mitochondrially targeted yellow fluorescent protein (YFP), no significant alterations in mitochondrial morphology were observed (Fig 3C and D). These findings were corroborated using high voltage transmission electron microscopy to image mouse brain and heart muscle mitochondria (Fig 3E). Hence, it appears that under basal conditions, and in multiple tissues, under the conditions tested, Pink1 deficiency did not affect mitochondrial localization or morphology. The synaptic dysfunction on the other hand clearly demonstrates that a Pink1 functional deficit is already present when morphology of the mitochondria is not yet affected, strongly arguing that this defect is upstream of morphological alterations observed by others (Clark et al, 2006; Exner et al, 2007; Park et al, 2006; Poole et al, 2008; Yang et al, 2006).
Mitochondrial membrane potential is decreased in the absence of Pink1

We therefore focused on the mitochondrial function, testing mitochondrial membrane potential by labelling NMJ synapses with JC-1. This potentiometric dye accumulates in the mitochondrial matrix as a function of the mitochondrial membrane potential ($\Delta \psi_m$) and forms J-aggregates which cause a green-to-red shift emission. Synaptic mitochondria of control flies showed a clear JC-1 red labelling that is completely disrupted by the mitochondrial uncoupler carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (Fig 4A). In contrast, synaptic mitochondrial uncoupler carbonylcyanide-4-clear JC-1 red labelling that is completely disrupted by the red-shift emission. Synaptic mitochondria of control flies showed $\Delta \psi_m$ potential of the mitochondrial membrane with JC-1. This potentiometric dye accumulates in the mitochondrial pathway, the oxidant H$_2$O$_2$ (Fig 4F) and the lipid second messenger arachidonic acid (Fig 4G) (Scorrano et al, 2003). Such an impairment could be the cause of increased susceptibility to apoptosis and cytochrome c release in Pink1 deficient cells. Pink1$^{-/-}$ cells were indeed more sensitive to two Ca$^{2+}$-dependent apoptotic stimuli that act through the mitochondrial pathway, the oxidant H$_2$O$_2$ (Fig 4F) and the lipid second messenger arachidonic acid (Fig 4G) (Scorrano et al, 2003). The increased sensitivity to Ca$^{2+}$-dependent apoptosis caused by oligomycin in Pink1$^{-/-}$ cells (Fig 4E), suggesting a role for the PTP in this process. In conclusion, ablation of PINK1 causes a disturbance of the electrochemical gradient, the driving force of the permeability transition pore (PTP), a large membrane channel that participates in certain forms of cell death (Grimm & Brdiczka, 2007). The PTP inhibitor cyclosporine A (CsA) completely prevented mitochondrial depolarization (Grimm & Brdiczka, 2007). The PTP inhibitor cyclosporine A (CsA) completely prevented mitochondrial depolarization caused by oligomycin in Pink1$^{-/-}$ cells (Fig 4E), suggesting a role for the PTP in this process. In conclusion, ablation of PINK1 in both a mammalian and a Drosophila model results in a latent dysfunction of the mitochondria, which is sensitive to CsA and causes a disturbance of the electrochemical gradient, the driving force for ATP synthesis. Such an impairment could be the cause of increased susceptibility to apoptosis and cytochrome c release in Pink1 deficient cells. Pink1$^{-/-}$ cells were indeed more sensitive to two Ca$^{2+}$-dependent apoptotic stimuli that act through the mitochondrial pathway, the oxidant H$_2$O$_2$ (Fig 4F) and the lipid second messenger arachidonic acid (Fig 4G) (Scorrano et al, 2003). The increased sensitivity to Ca$^{2+}$-dependent mitochondria-mediated apoptotic stimuli was also observed in purified mitochondria from Pink1$^{-/-}$ liver in vitro. The release of
cytochrome c upon stimulation with the proapoptotic BH3-only member of the Bcl-2 family cBID, was slightly, but significantly increased in purified Pink1−/− mitochondria (Fig 4H). Thus, mitochondria lacking Pink1 have a lowered threshold for PTP opening, are more susceptible to Ca2+-dependent apoptotic stimuli and release more cytochrome c in response to cBID (Scorrano et al, 2002).

**PINK1 deficit results in reduced Complex I activity**

Notably, PTP can be controlled by electron flux through Complex I of the respiratory chain (Fontaine et al, 1998), which is the target of both rotenone and MPTP. We therefore measured rates of oxygen consumption of mitochondria isolated from Pink1+/+ and Pink1−/− mouse liver and energized with substrates feeding electrons at the different respiratory chain complexes. Interestingly, the ratio of ADP-stimulated (State 3) to basal (State 4) oxygen consumption rate was significantly decreased in Pink1−/− mitochondria when they were energized with the Complex I substrates glutamate and malate (Fig 5A), whereas no differences were observed when mitochondria were energized with substrates feeding electrons at Complex II (succinate) or Complex III/IV (TMPD/ascorbate). The deficit in Complex I was confirmed by direct measurements of enzymatic activity in mitochondrial homogenates (see Fig 1A and B, respectively). Our preliminary experiments also could not reveal significant alterations in expression levels of various individual components of Complex I between Pink1+/+ and Pink1−/− mitochondria (Supporting Information Fig 1C and D). Thus, the deficit in Complex I is functional and not directly reflecting significant alterations in assembly or expression of Complex I.

**Relevance of the Complex I deficit for genetic PD**

To determine if the defects in Complex I are relevant to the aetiology of PD, we determined whether clinical mutations of PINK1 affect Complex I activity. Pink1−/− cells were rescued with human wild-type or with PINK1-containing clinical mutations (Fig 6A). Human PINK1 (hPink1res) fully complemented Complex I enzymatic activity in Pink1−/− mouse.
fibroblasts (Fig 5B and 6B). In contrast, two PD PINK1 clinical mutations G309D (Gly309 → Asp) and W437X (Trp437 → Xxx) as well as an artificial mutation K219A (Lys219 → Ala) that inactivates the kinase domain (Silvestri et al, 2005) were not effective (Fig 6A and B). Notably, expression of these PINK1 mutants did not alter the activity of the other ETC complexes (data not shown). Hence, cells expressing only PINK1 carrying PD mutations display a severe Complex I dysfunction similar to that found in mitochondria of Pink1−/− cells. We also measured synaptic function in pink1B9 Drosophila mutants that neuronally express human PINK1 (hpink1) or a clinical mutant G309D (Gly309 → Asp) (hpink1G309D). Expression of human PINK1, but not its clinical mutant G309D rescues mobilization of RP vesicles (Fig 6C and D). Combined together, the data indicate that cellular defects in PINK1 mutants arise from dysfunction of Complex I of the ETC and extend the critical role of Complex I as a factor in the progression of PD from sporadic to genetic forms of the disease.

**DISCUSSION**

Available evidence suggests impairment of the mitochondrial respiratory chain in sporadic and toxin-induced PD. However, a more suggestive link to mitochondrial dysfunction comes from...
studies have shown that mutations in the mitochondrial protein PINK1 are sufficient to cause the disease (Valente et al., 2004a,b). Previous studies (Clark et al., 2006; Exner et al., 2007; Park et al., 2006; Poole et al., 2008; Yang et al., 2006) showed altered mitochondrial morphology in loss of function PINK1 cells and animal models, but the exact mode of action of PINK1 remained unclear. We demonstrate here a key defect in the ETC at the level of Complex I caused by Pink1 loss of function, and the first synaptic phenotype caused by Pink1 deficiency. We observed deficits in Complex I driven respiration and specific Complex I enzymatic activity in different tissues of two different species, even before any alteration in mitochondrial morphology could be observed at the light and electron microscopic levels. Moreover, this deficit is completely eliminated when wild type PINK1 but not PINK1 containing clinical mutations is reintroduced, further arguing that this deficit is an upstream event in the pathological cascade induced by PINK1 loss of function.

Recent work has strongly drawn the attention to the mitochondrial fragmentation and other morphological abnormalities associated with PINK1 deficiency (Clark et al., 2006; Deng et al., 2008; Exner et al., 2007; Park et al., 2006; Poole et al., 2008; Yang et al., 2006). We did not observe gross alterations in mitochondrial morphology or synaptic localization, a trait dependent on mitochondrial fission, in both Drosophila and mouse-mutant cell lines (Li et al., 2004; Verstreken et al., 2005). Mitochondrial morphology changes were observed neither at the EM detection level in 2-month old mouse brain and muscle (this study) nor in the striatum of 3-, 4- and 24-month old Pink1−/− mice (Gautier et al., 2008). Furthermore,
PINK1 affects Complex I activity in mitochondria

**Figure 6. PINK1 clinical mutations also show reduced Complex I function and concomitant defects in synaptic function.**

A. PD-related PINK1 mutants were transfected in PINK1−/− fibroblasts and expression levels were analysed by reverse transcriptase-PCR for mRNA detection.

B. Respiratory chain measurements performed on mitochondrial homogenates from PINK1 deficient fibroblast cell lines stably expressing human PINK1 (hPINK1res), PD-related PINK1 mutant hPINK1G309D and hPINK1W437X, and the artificial mutant hPINK1K219A. Spectrophotometric assays for Complex I activity (NADH:ubiquinone oxidoreductase, rotenone sensitive) were performed. Statistical analysis was done using the unpaired Student’s t-test, where \( p < 0.0006 \), where \( p < 0.004 \) and \( p < 0.01 \). Data represent the average ± SEM of five independent experiments. ns = non-significant. Values presented for Pink1−/−, Pink1−/− and hPINK1res were previously shown in Fig 6A.

C. D. Reserve pool (RP) labelling in pink1 mutants that neuronally express wild-type human hPink1 (u pinks30Y; elav-GAL4/UAS-hPink1) or the PD-related hPink1sCopD mutant (u pinks30Y; elav-GAL4/UAS-hPink1sCopD). Both the ECP and RP in these animals were labelled by electrically stimulating motor neurons of third instar fillets in HL-3 with 2 mM Ca²⁺-free for 10 min and then leaving the dye with the preparation to rest for 5 min following stimulation (C, ‘load’). ECP vesicles, but not RP vesicles, were subsequently re-mobilized by incubating preparations for 5 min in 90 mM KCl, 2 mM Ca²⁺ and after washing in Ca²⁺ free HL-3, the same synapses imaged after loading were imaged again (C, ‘unload’). Fluorescence intensity of loading and unloading, normalized to loading intensity of pink1 mutants that express hPink1 in their neurons, was quantified (D). Note that wild type hPink1 can rescue RP labelling while hPink1sCopD cannot. Comparison of RP labelling in u pinks30Y and u pinks30Y; elav-GAL4/UAS-hPink1sCopD is not statistically significantly different. Statistical analysis was performed using the unpaired Student’s t-test, where \( p < 0.005 \). \( p < 0.02 \) when compared to control. ns = non-significant. The number of animals tested is indicated in the bar graphs and error bars indicate SEM. White bars: load; black bars: unload.

notwithstanding the many attempts to place Pink1 in the core machinery regulating mitochondrial fusion, a direct link between levels of Pink1 and rate of mitochondrial fusion has not been demonstrated. Since mitochondrial dysfunction, irrespective of the underlying mechanism, is accompanied by fragmentation of the organelle (Dimmer et al, 2008; Rojo et al, 2002), it is likely that the excess mitochondrial fission caused by ablation of Pink1 under certain experimental conditions is an epiphenomenon of the primary mitochondrial dysfunction sustained by reduced Complex I activity (Fig 7). Furthermore, this is entirely consistent with recent data on genetic interactions between the mitochondrial fusion and fission machinery and pink1 (Poole et al, 2008; Yang et al, 2008). Indeed, the data are consistent with an alternative model where Pink1 is not directly involved in mitochondrial dynamics, but they signify a convergence on a similar phenotype.

Recently, Gautier and co-workers described more general deficiencies of the mitochondrial respiration chain in Pink1 deficient mouse brain (Gautier et al, 2008), appearing as changes in state 3 respiration driven by Complex I and Complex II substrates. However, in our studies, a careful analysis of the ratio between phosphorylating (State 3) and basal rate (State 4) respiration showed no difference between Pink1−/− and Pink1−/− mitochondria energized with the Complex II substrate succinate. This is further supported by the normal enzymatic activity of Complex II as measured in knockout organelles.

Moreover, maximal (uncoupled) respiration was impaired in Pink1−/− mitochondria energized with glutamate, but not with succinate (data not shown), further confirming a specific defect in Complex I rather than a more general problem in ADP:ATP exchange which would be detected irrespective of the substrate used. Gautier et al (2008) proposed that altered mitochondrial dynamics could cause a more general respiration defect, however no evidence was provided. The alternative interpretation (see Fig 7) is equally possible however, as changes in mitochondrial shape might follow a primary mitochondrial dysfunction, for example via calcineurin and fission regulator Drp1 (Cereghetti et al, 2008).

A deficient Complex I function may indeed explain the many different phenotypes described in Pink1 deficient mice and flies, as schematically represented in Fig 7. Loss of Complex I would result in the reduction of the mitochondrial electrochemical gradient, observed in our study, and therefore promote the opening of the voltage-dependent PTP, which can in turn cause increased cytochrome c release and cell death (Irwin et al, 2003). Reduced Complex I activity can lead to increased levels of ROS production as found in several studies (Anichtchik et al, 2008; Piccoli et al, 2008). Loss of Complex I in synaptic mitochondria also results in impaired ATP production, which apparently underlies the RP mobilization defects that occur during intense stimulation of the synapse as mentioned here. This RP defect in the pink1 mutants is highly reminiscent of (albeit not as severe as) that observed in drp1 mutants (Verstreken et al, 2005). Drp1 mediates mitochondrial fission and its overexpression in neurons results in excess synaptic mitochondria (Li et al, 2004). Loss of Drp1 leads to depletion of synaptic mitochondria and decreased local mitochondrial ATP production that is used
by the myosin ATPase to mediate RP mobilization (Verstreken et al, 2005; Ryan, 1999). Consistent with this hypothesis, ATP levels in *pink1* mutant flies are reduced compared to controls (Clark et al, 2006), providing an explanation for the neuronal defects we observe in *pink1* mutants.

One tantalizing question in PD research is why Pink1 deficiency results in quite robust phenotypes in *Drosophila*, while in mice the effects are much less pronounced. However, even *Drosophila pink1* deficient mitochondria remain quite functional under most conditions and appear to generate sufficient energy to maintain, for instance, basal neuronal transmission. All these strongly indicate that efficient compensation mechanisms allow Pink1 deficient cells to cope with the partial Complex I dysfunction. The analogy with the clinical *PINK1* mutations (which as we showed cause similar Complex I defects) is intriguing: while such mutations are present in many cells and tissues of the human body right from the time of conception, it is only late in life, and only in particular brain areas such as the substantia nigra and striatum, that Pink1 deficiency results finally in clinical phenotypes. Thus, one could postulate that compensation mechanisms allow systems to cope for many years with the defect, and additional stress, caused by ageing and/or oxidative dopamine metabolism, probably leads to effective impairment of the system.

In conclusion, our work provides genetic evidence that mutations found in a subset of autosomal recessive PD are impinging on the same central pathogenic event: impairment of Complex I activity. Apparently, the enzymatic activity of Complex I depends on the integrity of the kinase domain of PINK1. Further work is needed to investigate whether Pink1 directly affects the phosphorylation status of Complex I components, or whether it acts indirectly, via intermediate additional proteins, such as phosphorylation substrates of PINK1. Regardless, our work provides additional support to the hypothesis that the dysfunction of Complex I is an important and early event in the pathogenesis of Pink1-associated PD. It is interesting to note that Complex I has also been strongly implicated in the pathogenesis of (some forms of) sporadic PD.

**MATERIALS AND METHODS**

**Generation of conditional Pink1 knockout mice and derived mouse embryonic fibroblast (MEF) cell lines**

To generate the targeting vector construct 129/Ola, genomic DNA fragments were amplified by polymerase chain reaction (PCR). PsK62-easyflox was used as a vector. A 5'-fragment consisting of 3 kb of intron 1, which was 1366 basepairs (bp) downstream of the end of exon 1, was inserted. Then a 2 kb floxed homologous arm was inserted. It consisted of a loxP site, a neomycin resistance cassette flanked by frt sites, and exons 2 and 3 and a second loxP site that was 504 base pairs downstream the end of exon 3. A 3.9 kb 3'-homology arm consisting of exons 4, 5, 6, and part of exon 7 was added at the 3'-end of the homologous arm. Deletion of exons 2 and 3 by Cre-mediated recombination leads to a frameshift, thereby creating a truncation of Pink1 protein after exon 1. The linearized vector was electroporated into TBEV2 embryonic stem cells. Neomycin resistant clones were
The paper explained

PROBLEM:
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder. The etiology of PD remains unknown, although there is evidence pointing to the involvement of abnormal protein aggregation, oxidative stress and mitochondrial dysfunction. The recessive PD gene PINK1 encodes a mitochondrial serine/threonine kinase and it appears to affect the mitochondrial dynamics. A mechanistic link between Pink1 and proteins directly involved in mitochondrial dynamics has however not been demonstrated.

RESULTS:
Using *Drosophila* and mouse models, we show here that an early effect of PINK1 deficiency is the disruption of Complex I function, which results in mitochondrial membrane depolarization, increased sensitivity to apoptotic stress and synaptic transmission deficits in *Drosophila* neurons. The fundamental importance of Pink1 for energy maintenance under increased demand is further corroborated as this deficit can be rescued by adding ATP to the synapse. The clinical relevance is demonstrated by the fact that human wild type PINK1 but not PINK1-containing clinical mutations can rescue Complex I deficiency.

IMPACT:
This study is important as it suggests an alternative hypothesis regarding the role(s) of Pink1 in the mitochondria and in PD. Rather than affecting directly the mitochondrial dynamics, PINK1 mutations affect Complex I activity and this primary effect is upstream of other mitochondrial alterations and PD phenotypes associated with PINK1 mutations.

Screened for homologous recombination by Southern blot. Accurately targeted ES cell clones were expanded and injected into blastocysts originating from C57BL/6 female mice. Blastocysts were transferred into pseudopregnant foster mothers to give birth to chimeras. Chimeras were bred to C57BL/6 wild type mice and their offspring was screened for germline transmission by Southern blot.

Pink1 conditional knockout mice were bred to Cre Deleter animals (Schwenk et al, 1995) with C57BL/6 background to create Pink1 complete knockout mice.

Heterozygous Pink1 knockout mice (*Pink1<sup>+/−</sup>*) were interbred to generate mutant mice and wild type littermate controls. Embryonic day 13 embryos were dissected, heads and red organs were removed and used for genotyping by Southern blot. The rest of the bodies were chopped up in cell culture dishes containing Dulbecco’s Modified Eagle’s Medium (DMEM) supplied with 50% foetal calf serum (FCS) and 1% penicillin/streptomycin. Cultures were expanded and serum concentration was constantly decreased to 10% FCS serum and 1% penicillin/streptomycin. Cultures were expanded and serum concentration was constantly decreased to 10% FCS after they reached consistent growth. Afterwards the cultures were immortalized by transfection with simian virus 40 (SV40) large T antigen.

Site-directed mutagenesis and generation of stable cell lines

hPINK1 construct was obtained from Origene (USA). Clinical hPINK1 PD mutants G309D (Gly309→Asp) and W437X (Trp437→Stop), and the artificial mutant K219A (Lys219→Ala) were constructed using the multisite-directed mutagenesis kit according to the supplier’s instructions (Stratagene). To confirm expression of hPINK1 in the transduced fibroblast cell lines, total RNA from these cell lines were extracted using standard methods and prepared for subsequent analysis.

**Morphometric analysis**

Morphometric analysis was performed as described previously (Cipolat et al, 2004) and examined on an Olympus IX81 inverted microscope equipped with a CellR imaging system (Olympus). For details see the Supporting Information.

**Histology**

Two-month old mice were perfused through the left ventricle with cacodylate buffer (0.1 M, pH 7.4) followed by Karnovsky fixative (2% paraformaldehyde +2.5% glutaraldehyde) in cacodylate buffer. The brain and heart (muscle) were removed and cut into 2 mm × 3 mm pieces, which were fixed overnight in Karnovsky fixative. The samples were rinsed with cacodylate buffer, post-fixed by immersion in 2% osmium tetroxide for 2 h, dehydrated in a graded ethanol series (pre-stained for 30 min with 1% aqueous uranylacetate in 70% ethanol step), immersed in propylene oxide and embedded in Agar 100 resin (Epon-equivalent, polymerized at 60°C). Ultrathin sections (70 nm) were cut with a Leica Ultracut UCT ultramicrotome and placed on 400-mesh copper Formvar carbon-coated grids. Grids were negatively stained with 4% saturated aqueous uranyl acetate (5 min) and Reynolds’s lead citrate stain (3 min). Samples were examined through a JEOL JEM-2100 microscope at the K.U. Leuven Electron Microscopy Core Facility of the Department of Human Genetics, Leuven, Belgium.

**Flow cytometry**

Evaluation of apoptosis was performed as described previously (Frezza et al, 2006), cells were treated with increasing concentrations of H<sub>2</sub>O<sub>2</sub> and arachidonic acid. Cells were analysed by flow cytometry. Viability was measured as the percentage of Annexin-V, propidium iodide (PI) negative cells.
Real-time imaging of mitochondrial membrane potential
For evaluation of the membrane potential, fibroblast cells were grown in 3 cm plastic dishes with glass coverslips (Nunc) and the procedure was performed as described previously (Alirol et al, 2006). For details see the Supporting Information.

Mitochondrial isolation
Mitochondria were isolated from fibroblast cells and from 2-month old mouse liver and brain as described previously (Frezza et al, 2007). Fly heads (brain enriched) and thoraxes (muscle enriched) were homogenized and mitochondrial homogenates were purified as described by Walker et al (2006). For additional details, see the Supporting Information.

Cytochrome c release ELISA
Cytochrome c release in response to recombinant p7/p15 bid-mediated immunodepletion (BID) was determined as described previously (Frezza et al, 2006). For additional details see the Supporting Information.

Respiratory assays
Mitochondrial oxygen consumption was determined for liver mitochondria by using a Clarke-type oxygen electrode (Hansatech Instruments) as described previously (Frezza et al, 2006). Oxidative phosphorylation complex measurements performed on mitochondrial homogenates from fibroblast cells, mouse brain, fly brain and muscle-enriched tissue were analysed by spectrophotometric assays as described previously (de Paepe et al, 2006). See additional details in Supporting Information. For statistical analysis, all the measurements were analysed by Student's t-test.

Drosophila genetics
The w pink1^{REV} controls and w pink1^{B9} flies were kindly provided by Jeehye Park and Jongkyeong Chung (Korea Advanced Institute of Science and Technology) (Park et al, 2006) and mutant larvae were selected using green fluorescent protein (GFP) balancers. UAS-hPink1 and UAS-hPink1^{C109D} flies were kindly provided by Zhohuha Zhang (Brenham Institute for Medical Research) (Wang et al, 2006) and were expressed in w pink1^{B9} mutants using the elav-GAL4 driver (obtained from the Bloomington Stockcenter). UAS-MitoGFP D42-GAL4 flies were kindly provided by William Saxton (Indiana University) and male w pink1^{B9}/H; UAS mito-GFP D42-GAL4 e/+ larvae were used in our analyses.

JC-1 and MitoGFP labelling
Larval fillets were labelled with JC-1 (Molecular Probes) as described previously (Verstreken et al, 2005). FCCP, an uncoupler, was added at a final concentration of 50 nM. MitoGFP imaging was performed exactly as described by Verstreken et al (2005). Images were captured on a BioRad Radiance microscope or on a Nikon FN-1 microscope with a DS-2MBWc digital camera, 40× water objective, numerical aperture (NA) 0.8 and quantification of labelling intensity was performed using Image-J. Forward filling of motor neurons with 1 mM ATP was performed as described previously (Verstreken et al, 2005). Briefly, larval fillets with cut motor neurons were incubated in HL-3 with 0.5 mM CaCl2 and 1 mM ATP, and the motor neuron innervating an abdominal hemisegement 2 was sucked into a suction electrode such that the end of the motor neuron is in contact with HL-3 with ATP. The bath solution was then replaced with HL-3 with 1 mM CaCl2 and preparations were incubated for 30 min. Following incubation, 4 mM (final) FM1–43 was added and the filled motor neuron was stimulated to label RP vesicles as described above. KCl unloading was performed in the presence of 1 mM ATP.

Acknowledgements
We thank Sven Vilain for assistance with the Drosophila manipulation. This work was supported by the Fund for Scientific Research, Flanders; KU Leuven; Federal Office for Scientific Affairs (IUAP P6/43/), Belgium; a Methusalem grant of the Flemish Government, VIB; and a Marie Curie Excellence Grant (MEXT-CT-2006-042267). VAM is a Marie Curie post-doctoral researcher. LS is a Senior Telethon Scientist of the Dulbecco-Telethon Institute and research in his laboratory is supported by Telethon Italy and AIRC Italy. CF is supported by a ‘Winte’ fellowship of AIRC. The work of WW was supported by the Deutsche Forschungsgemeinschaft (SFB596), the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN) Förderkennzeichen 01GS0476, 01GR0430 and 01GN0512.

Supplementary information is available at EMBO Molecular Medicine online.

The authors declare that they have no conflict of interest.

For more information
OMIM, Online Mendelian Inheritance in Man:
Parkinson’s disease:
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=168600
pink:
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=608309
The Michael J. Fox Foundation for Parkinson’s Research:
http://www.michaeljfox.org/
Database of Drosophila Genes and Genomes:
http://flybase.org/
Human disease to Drosophila Gene Database:
http://superfly.ucsd.edu/homophila/
Bart de Strooper’ Laboratoy:
http://med.kuleuven.be/cme-mg/incb/index.html
PINK1 affects Complex I activity in mitochondria

References

Allrol E, James D, Huber D, Marchetto A, Vergani L, Martineou JC, Scorrano L (2006) The mitochondrial fission protein Nfia is required for the endoplasmic reticulum gateway to induce apoptosis. J Biol Cell 17: 4593-4605

Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P, Rubinstein DC (2008) Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 28: 8199-8207

Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann NY Acad Sci 991: 120-131

Bellina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Beal MF (2003) Mitochondrial dysfunction in idiopathic Parkinson’s disease. J Neurosci Res 72: 15803-15808

Biskup S, Moore DJ, Celii F, Higashi S, West AB, Andradi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, et al (2006) Localization of Drp1 to membrane and vesicular structures in mammalian brain. Ann Neurol 60: 557-569

Cereghetti GM, Stangherlin A, Martins de Brito O, Chang CR, Blackstone C, Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Beal MF (2006) Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann NY Acad Sci 991: 120-131

Clark IE, Dodson MW, Jiang C, George E, Matthys D, van Maldergem L, Scorrano L, Bernardi P, Scorrano L (2008) Diphosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci USA 105: 15803-15808

Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L (2004) OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA 101: 15927-15932

Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166

Cole NB, Dieulis D, Leo P, Mitchell DC, Nussbaum RL (2008) Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res 314: 2076-2089

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39: 389-409

Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302: 819-822

de Paepe B, Smet J, Leroy JG, Seneca S, George E, Matthys D, van Maldergem L, Scorrano L, Bernardi P, Scorrano L et al (2006) Diagnostic value of immunostaining in patients with oxidative phosphorylation defects. Pediatr Res 59: 2-6

Deng H, Dodson MW, Huang H, Guo M (2008) The Parkinson’s disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105: 14503-14508

Deng H, Jankovic J, Guo Y, Xie W, Le W (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun 337: 1133-1138

Devli I, Raghavendra V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089-9100

Dimmer KS, Navoni E, Casarin A, Trevisson E, Endele S, Winterpacht A, Salviati L, Scorrano L (2008) LETM1, deleted in Wolf-Hirschhorn syndrome is required for normal mitochondrial morphology and cellular viability. Hum Mol Genet 17: 201-214

Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hopenhien HK, Gasser T, et al (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27: 12413-12418

Fontaine E, Eriksson O, Ichas F, Bernardi P (1998) Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation by electron flow through the respiratory chain complex I. J Biol Chem 273: 11662-11668

Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Bezroukou TD, Bartoli D, Polishchuk RS, Danial NN, De Strooper B, et al (2006) OPA1 controls apoptotic crista remodeling independently from mitochondrial fission. Cell 126: 177-189

Frezza C, Cipolat S, Scorrano L (2007) Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2: 287-295

Gandhi PN, Wang X, Zhu X, Chen SC, Wilson-D offline AS (2008) The Rod domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86: 1711-1720

Gautier CA, Kitada T, Shen J (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 105: 11364-11369

Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100: 4078-4083

Grimm S, Brdiczka D (2007) The permeability transition pore in cell death. Apoptosis 12: 841-855

Iaccarino C, Cioso C, Vitale C, Sanna G, Carri MT, Barone P (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16: 1319-1326

Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Meigijhan A, Merlini L, Braghetta P, Columbaro M, Volpin D, Bressan GM, et al (2003) Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 35: 367-371

Jenner P, Olano CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47: S161-170

Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, Chung J (2008) PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 377: 975-980

Kitada T, Pisani A, Porter DR, Yamaguchi H, Tischerer A, Martelta G, Bonsi R, Zhang C, Pothos EN, Shen J (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci USA 104: 11441-11446

Kosel S, Hofhaus G, Maassen A, Vierregge P, Graeber MB (1999) Role of mitofusin 1 in mitochondria in Parkinson disease. Biol Chem 380: 865-870

Kuromi H, Kidokoro Y (2002) Selective replenishment of two vesicle pools depends on the source of Ca++ at the Drosophila synapse. Neuron 35: 333-343

Li Z, Okayama K, Hayashi Y, Sheng M (2004) The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119: 873-887

Lin W, Kang UJ (2008) Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 106: 464-474

Mandemakers W, Moraes VA, De Strooper B (2007) A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci 120: 1707-1716

Moriwaki Y, Kim YJ, Ido Y, Miyawaka K, Endo S, Takahashi R (2008) LRRP7 PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci Res 61: 43-48

Narendra D, Tanaka A, Suen DJ, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795-803

Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614-18621

Panov A, Dikalov S, Shalbuevna Y, Taylor G, Sherer T, Greenamyre JT (2005) Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 280: 40206-40215

Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, et al (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 442: 1157-1161

Parker WD Jr, Swerdlow RH (1998) Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet 62: 758-762

Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131: 2183-2194
Petit A, Kawarai T, Paitei E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, et al (2005) Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 280: 34025-34032
Piccoli C, Sardanelli A, Scrima R, Ripoli M, Quarato G, D’Aprile A, Bellomo F, Scacco S, De Michele F, Fillia A, et al (2008) Mitochondrial respiratory dysfunction in familial parkinsonism associated with PINK1 mutation. Neurochem Res 33: 2565-2574
Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, et al (2007) The mitochondrial protease Htra2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat Cell Biol 9: 1243-1252
Polo AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105: 1638-1643
Pridgeon JW, Olzmann JA, Chin LS, Li L (2004) The mitochondrial protease Htra2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat Cell Biol 9: 1243-1252
Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, et al (2007) The mitochondrial protease Htra2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat Cell Biol 9: 1243-1252
Polo AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105: 1638-1643
Pridgeon JW, Olzmann JA, Chin LS, Li L (2004) The mitochondrial protease Htra2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat Cell Biol 9: 1243-1252
